Truemeds crossed ₹315 crore ($33 million, at $1 ≈ ₹96.0 as of 18 September 2026, Trading Economics) in gross revenue in the year to March 2024, roughly double the ₹154 crore of the year before, according to Entrackr’s reading of its Registrar of Companies filings. It reached that number by doing something most pharmacies would never do on purpose: talking customers out of the exact medicine their doctor wrote on the prescription.
The Mumbai company, run by the entity Intellihealth Solutions Private Limited, sells generic and branded-generic alternatives to the drugs people are prescribed, and its pitch to the patient is that the swap is clinically equivalent and much cheaper. That is a strange thing to build a business on, because the more successfully Truemeds persuades a customer to trade down, the lower the price on the invoice. This piece traces how that model was funded, what it actually earns, and why, by August 2026, a still-loss-making eight-year-old was reportedly trying to buy a former ₹14,000 crore-valued grocery startup with the cash on its balance sheet.
Quick facts
| Company | Truemeds, operated by Intellihealth Solutions Private Limited, Mumbai |
| Founded | 2019 |
| Founder(s) | Akshat Nayyar (CEO) and Dr Kunal Wani, both formerly at Abbott’s India pharma business |
| Businesses | Online pharmacy focused on generic and branded-generic substitutes, plus teleconsultation and diagnostics, sold direct to consumers via app and website |
| Latest FY revenue | ₹315 crore gross revenue in FY24 (year ended March 2024), per RoC filings; company-stated revenue of about ₹500 crore in FY25 |
| Latest FY profit/loss | Net loss of ₹61 crore in FY24 (RoC filings), narrowed from ₹67 crore in FY23 |
| Listed | Private |
| Market value / last valuation | Over $400 million after an August 2025 secondary sale; about $340 million at the March 2025 Series C (reported) |
| Key shareholders | WestBridge Capital (reported ~28.6%), Info Edge Ventures (~23%), Peak XV Partners, Accel (~10%) |
What they do
Truemeds is an online pharmacy. A customer uploads a prescription, and the platform, alongside filling exactly what the doctor wrote, offers a generic or branded-generic version of the same molecule at a lower price, with a teleconsultation from an in-house doctor to reassure the buyer that the substitute is clinically the same. The company describes its core buyer as the chronic-care patient, the person managing diabetes, hypertension or cardiac disease, who refills the same basket of medicines month after month and for whom a persistent discount compounds into real household savings. Truemeds says more than three quarters of its customers come from tier-2 cities and beyond, and per TechCrunch’s August 2025 reporting it served an average of 500,000 monthly active customers, across a base of about 3 million customers to date, delivering to more than 20,000 postal codes.
The origin
The founding insight came from inside the drug industry, not from outside it. Akshat Nayyar spent years in consulting and then ran the Project Management Office for Abbott’s roughly $1 billion India pharmaceutical business between 2015 and early 2019, and his co-founder Dr Kunal Wani, an MBBS who had worked in medical roles at Boehringer Ingelheim, UCB and Panacea Biotec before also joining Abbott, came from the clinical side. What they saw from that vantage point was a pricing gap the branded market was built to preserve: the same molecule could sell as an expensive branded drug or as a cheap generic, and a large share of Indian patients, by the founders’ account, do not complete their prescribed course because they cannot afford the branded version. When they started Truemeds in 2019, India’s e-pharmacy market was already crowded with well-funded players, PharmEasy, Tata 1mg, Netmeds, Amazon and Flipkart-owned entrants, mostly competing on discounts against the same branded catalogue. Rather than fight that discount war on branded drugs, Truemeds chose a narrower position: steer the customer to the generic equivalent, own the margin that the branded supply chain normally keeps, and make the low price the product rather than a promotion.
The struggle years
The hard part of this model is not logistics; it is trust. Persuading a patient, and often the family member who actually pays, to abandon the brand name their doctor wrote and take an unfamiliar generic instead runs against decades of conditioning that expensive medicine is safer medicine. Truemeds’ answer was to wrap every substitution in a doctor teleconsultation, which is why the company reports running on the order of 10 to 12 million consultations a year: the consult is not a side feature, it is the mechanism that makes the trade-down acceptable to a nervous buyer. That trust cost is expensive to buy at scale, and it shows in the accounts. The company was loss-making throughout its growth phase, losing ₹67 crore in FY23 and ₹61 crore in FY24 on the way up, and its FY24 unit economics were still under water: Entrackr calculated that Truemeds spent about ₹1.23 to earn every ₹1 of operating revenue that year, with an EBITDA margin near negative 18%. It was also spending heavily to acquire the customer in the first place, against entrenched rivals with far deeper balance sheets, at a time when the whole Indian e-pharmacy category was tightening after the 2021-2022 funding boom faded. The struggle, in short, was less a single near-death event than a long grind: convincing patients one consult at a time while burning capital to do it, in a market where the better-capitalised incumbents could simply outspend on the branded discounts Truemeds had chosen not to match.
The turning point
The clearest before-and-after is the FY23-to-FY24 revenue step. Gross revenue roughly doubled from ₹154 crore to ₹315 crore in the year to March 2024, and, unusually for a startup doubling its top line, the loss did not blow out to fund it: it fell slightly, from ₹67 crore to ₹61 crore, per the RoC filings read by Entrackr. That combination, revenue up about 105% while losses edged down, is the moment Truemeds stopped looking like a cash-burning experiment and started looking like a business with a working repeat-purchase engine, because the chronic-care customer who trusts the first generic swap keeps reordering it without a fresh acquisition cost each month. TechCrunch reported that Truemeds retains more than half of its revenue twelve months on, the retention signature of a refill business rather than a one-off discount hunt. That proof of durable repeat demand is what let the company raise at a sharply higher valuation in 2025, and it is the number the next section turns on.
The money behind it
Truemeds has raised more than $110 million across its rounds since 2020, according to Entrackr citing TheKredible; Tracxn’s tally puts the figure higher, at about $176 million, a reminder that private funding totals vary by which secondary and debt tranches a tracker counts. The rounds, by public record:
- Seed, April 2020: about $0.49 million, from Info Edge Ventures (Inc42 funding record).
- Series A, June 2021: about $5 million, from Info Edge Ventures, Asha Impact and the Indian Angel Network Fund (YourStory, June 2021).
- Series B, April 2022: $22 million, led by WestBridge Capital, with Info Edge, Asha Impact and IAN Fund participating (Entrackr and Business Standard, April 2022).
- Series C, in two closes across 2025: $85 million in total, led by Accel in the first close (about ₹375 crore / ~$44 million, March 2025) and Peak XV Partners in the second (about ₹174 crore / ~$20 million, mid-2025), with WestBridge and Info Edge following on (Entrackr and Inc42, 2025). TechCrunch reported the $85 million split as roughly $65 million of primary capital and $20 million of secondary.
Three backers shaped the company. Info Edge Ventures was there from the seed and kept following its money through every subsequent round, a rare full-cycle conviction bet. WestBridge Capital led the Series B that funded the scale-up and, per reporting around the Series C, is the largest shareholder at about 28.6%, with Info Edge at about 23% and Accel at about 10%. Peak XV Partners’ arrival in the second Series C close is what carried the valuation over $400 million after the August 2025 secondary sale, up from a reported ~$340 million at the March 2025 close and roughly $110 million at the prior round, a jump TechCrunch put at about 3.6 times.
How it makes money
The money mechanics are simpler than the trust mechanics. Where the money comes in and goes out, per the FY24 RoC figures reported by Entrackr:
- Revenue: almost entirely product sales. Medicines and medical devices made up 98.4% of operating income, which was ₹310 crore in FY24; total income including other items was ₹325 crore.
- The margin trick: because Truemeds pushes buyers toward generics and branded-generics, it captures the spread the branded supply chain would otherwise keep, so a lower price on the invoice can still leave a workable gross margin. TechCrunch reported average discounts to the customer of about 32% (up from 29% a year earlier) and savings of roughly 47% for customers who switch from a brand.
- Largest cost: the medicines themselves. Cost of goods was ₹262 crore in FY24, about 68% of total expenditure of ₹386 crore.
- Other big costs: employee benefits of ₹42 crore, plus advertising, rent, technology, legal and other overheads, the block that has to shrink as a share of revenue for the model to reach profit.
- The part people get wrong: the teleconsultation is not a revenue line, it is a cost of conversion. Truemeds mostly does not charge for the doctor consult; it runs 10-12 million a year because the consult is what makes a customer accept the cheaper substitute, so it belongs in the cost of acquiring and retaining the sale, not in a separate services P&L.
The numbers
Gross revenue and net loss, in ₹ crore. FY23 and FY24 are from RoC filings as reported by Entrackr; the FY25 figure is company-stated (TechCrunch, August 2025) and had not yet been confirmed by an RoC filing at the time of writing.
| Financial year | Gross revenue (₹ crore) | Net profit/(loss) (₹ crore) |
|---|---|---|
| FY23 | 154 | (67) |
| FY24 | 315 | (61) |
| FY25 (company-stated) | ~500 | Not disclosed |
The shape to notice is the one already flagged: revenue roughly doubling from FY23 to FY24 while the loss stayed flat rather than expanding, which is the opposite of the buy-growth-at-any-cost pattern common in Indian consumer startups. On the company-stated FY25 number, TechCrunch reported revenue of about ₹5 billion (₹500 crore, about $57 million) growing more than 66% year on year; treat it as management guidance until the filing lands.
Where the money comes from
The revenue mix is narrow by product and wide by geography, and the geography is the surprise:
- By product: medicines and medical devices were 98.4% of operating income in FY24 (Entrackr, RoC), so this is a pharmacy, not a diversified health platform, whatever the teleconsult volume suggests.
- By customer type: chronic-care patients (diabetes, hypertension, cardiac) are the core, because they refill monthly and drive the repeat orders behind the more-than-50% twelve-month revenue retention TechCrunch reported.
- By geography, the surprise: more than 75% of customers come from tier-2 cities and beyond, per TechCrunch, and Truemeds delivers to more than 20,000 postal codes. The affordability pitch that would be a marginal saving in a metro is a decisive one in smaller cities, so the company’s centre of gravity sits outside the big metros that most of its better-known rivals fought over.
- Scale markers: about 500,000 monthly active customers and around 3 million customers to date, served from 19 fulfilment centres, with roughly 2,800 employees, as reported by TechCrunch in August 2025.
The risks
Three concrete risks, each with a mechanism:
- Regulatory overhang on e-pharmacy itself. India has repeatedly signalled tighter rules for online medicine sale, and any move that constrains substitution, prescription handling or discounting would hit Truemeds directly, because its entire edge is steering buyers to a cheaper molecule than the one prescribed. This is a policy risk shared across the sector, not specific to one filing.
- Still-negative unit economics and cash burn. On FY24 numbers Truemeds spent about ₹1.23 for every ₹1 of operating revenue with an EBITDA margin near negative 18% (Entrackr). The model only works if overheads and acquisition costs keep falling as a share of revenue; if growth slows before that crossover, the loss reopens.
- A cash-led acquisition that could distract or dilute. In August 2026, Inc42 and other outlets reported Truemeds was in talks to acquire the grocery startup DealShare for about $90 million in a share swap, valuing Truemeds itself at around $600 million in the deal, with the logic reportedly centred on DealShare’s more-than-$90-million cash pile and its distribution reach in smaller cities rather than its operating business. If accurate, buying a company essentially for its bank balance is a sign of ambition, but folding in a distressed grocery operation (DealShare was valued at roughly $1.7 billion at its 2022 peak, so this would be about 95% below that) carries real integration and focus risk for a firm that is not yet profitable. The deal was reported, not confirmed, at the time of writing.
The takeaway
The transferable lesson is about where a latecomer can win. Truemeds entered a market that looked closed, five or more funded players already discounting the same branded catalogue, and instead of matching the discount it changed the product being sold: not a cheaper version of the branded drug, but a different drug entirely, the generic, wrapped in enough clinical reassurance that a cautious patient would accept the switch. That reframing turned the incumbents’ strength, their branded-discount war chests, into a fight Truemeds simply refused to have, and it found its growth in the tier-2 towns where the saving mattered most. The broader point for any founder staring at a crowded market: the opening is rarely a better version of what everyone sells; it is more often a different answer to the same customer need, positioned where the incumbents are not looking.
Frequently asked questions
What does Truemeds do?
Truemeds is a Mumbai-based online pharmacy, run by Intellihealth Solutions Private Limited, that fills prescriptions and offers generic or branded-generic substitutes at lower prices, supported by an in-house doctor teleconsultation. It focuses on chronic-care patients and, per TechCrunch’s August 2025 reporting, draws more than 75% of its customers from tier-2 cities and beyond.
Who founded Truemeds and when?
Truemeds was founded in 2019 by Akshat Nayyar, its CEO, and Dr Kunal Wani. Both previously worked at Abbott’s India pharmaceutical business; Nayyar had run its Project Management Office and Wani, an MBBS, came from clinical and medical-affairs roles across several drug companies.
How much has Truemeds raised, and what is it worth?
Truemeds has raised more than $110 million since 2020 according to Entrackr (Tracxn puts the figure nearer $176 million), across a seed, Series A, a $22 million Series B led by WestBridge in 2022, and an $85 million Series C completed in two closes in 2025 led by Accel and Peak XV Partners. Its valuation was reported at over $400 million after an August 2025 secondary sale, up from about $340 million at the March 2025 Series C.
Is Truemeds profitable?
Not as of its latest filed accounts. Truemeds reported a net loss of ₹61 crore in FY24 (year ended March 2024) on gross revenue of ₹315 crore, per RoC filings read by Entrackr, an improvement on the ₹67 crore loss of FY23. Company-stated FY25 revenue was around ₹500 crore, but a profit figure had not been confirmed in an RoC filing at the time of writing.
Is Truemeds buying DealShare?
In August 2026, Inc42 and other outlets reported that Truemeds was in talks to acquire the grocery startup DealShare for about $90 million via a share swap, with the rationale reportedly focused on DealShare’s cash reserves of over $90 million and its distribution reach in smaller cities. The talks were reported, not confirmed, and should be treated as unconfirmed until the companies disclose a completed transaction.
Sources
Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).
- Entrackr / Fintrackr, “Info Edge-backed Truemeds’ gross revenue crosses Rs 300 Cr in FY24,” 2024 (FY24 and FY23 revenue, loss, expense breakdown, unit economics)
- Entrackr, “Truemeds closes $85 Mn Series C round led by Accel and PeakXV,” August 2025
- TechCrunch, “Truemeds challenged how Indians buy medicine and saw a 3.6x jump in valuation,” August 2025 (valuation, orders, customers, retention, discounts, FY revenue, headcount, fulfilment centres)
- Inc42, “Truemeds Total Funding / funding rounds” company page, accessed September 2026 (round dates and amounts)
- Inc42, “Truemeds Eyes DealShare Acquisition At $90 Mn, 95% Below Peak Valuation: Report,” August 2026
- CXO Digitalpulse, “Healthtech Startup Truemeds Raises $20 Million in Series C Round Led by Peak XV, Valuation Crosses $400 Million,” 2025
- YourStory, “Healthtech startup Truemeds raises $22M in Series B, WestBridge Capital,” April 2022; and Truemeds company profile, 2026
- Business Standard, “Truemeds raises $22mn in Series B funding round led by WestBridge Capital,” April 2022
- BW Disrupt, “E-pharmacy Platform Truemeds Secures $85 Mn In Two Closes From Accel, Peak XV, WestBridge, Info Edge,” 2025 (investor stakes)
- WestBridge Capital, founder profile, “Akshat Nayyar – Truemeds,” accessed September 2026 (founder background)
- Truemeds, “Dr. Kunal Wani, Co-Founder” author profile, accessed September 2026 (co-founder background)
Found an error? Write to us and we’ll correct it in the open, dated, on the piece.